The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of olutasidenib in combination with azacitidine followed by olutasidenib maintenance after venetoclax plus a hypomethylating agent regimen for IDH1-mutated acute myeloid leukemia (University of California Hematologic Malignancies Consortium Study 2441).
 
Brian Jonas
Consulting or Advisory Role - Abbvie; Advarra; BMS; Daiichi Sankyo; Genentech; Gilead Sciences; Kura Oncology; Rigel; Schrodinger; Syndax; Treadwell Therapeutics
Research Funding - Abbvie (Inst); Amgen (Inst); Aptose Biosciences (Inst); AROG (Inst); Biomea Fusion (Inst); BMS (Inst); Celgene (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Glycomimetics (Inst); Hanmi (Inst); Immune-Onc Therapeutics (Inst); Jazz Pharmaceuticals (Inst); Kymera (Inst); Loxo (Inst); Pfizer (Inst); Pharmacyclics (Inst); Treadwell Therapeutics (Inst)
 
Mohammad Bukari
Consulting or Advisory Role - Abbvie; Agios
 
Timothy Ferng
No Relationships to Disclose
 
Deepa Jeyakumar
Research Funding - Jazz Pharmaceuticals (Inst); Pfizer (Inst)
 
Caspian Oliai
Research Funding - Amgen (Inst); Arog (Inst); Electra (Inst); Jazz Pharmaceuticals (Inst); Orca Bio (Inst); Pfizer (Inst)
 
Tiffany Tanaka
Consulting or Advisory Role - Bristol-Myers Squibb; Geron; Gilead Sciences; SERVIER
Research Funding - Function Oncology (Inst)
 
Chiung-Yu Huang
No Relationships to Disclose
 
Francisco Socola
No Relationships to Disclose